Patient Enrollment The American College of Rheumatology has been notified by
Immunex Corp. of a potential etanercept drug supply issue. Based on the number
of new prescriptions written, the manufacturers have announced a potential period
of supply constraints for etanercept in 2001. They have announced an enrollment
program to help ensure uninterrupted future drug availability for those patients
currently receiving etanercept. Patient information provided for the enrollment
program will be used only for the purposes of administering the program.
should inform their etanercept-treated patients of the need to enroll by 12/31/00.
Patients can register by calling 1-888-4ENBREL (1-888-436-2735). They will provide
information including their name and mailing address over the phone. Patients
will be mailed a temporary enrollment card, and later a permanent card will
be issued that will be necessary to fill future prescriptions.
whom etanercept is prescribed after January 1 will also need to enroll by calling
1-888-4ENBREL. Patients will have access to Enbrel as additional supply becomes
receiving etanercept through the RA Assistance Foundation (RAAF) will continue
to receive drug from the manufacturer and need not enroll in the program. December
14, 2000 John J. Cush, MD Hotline Editor
John J. Cush, MD
provided by the ACR Communications and Marketing Committee as a service to members.
This Hotline reflects the views of the author(s) and does not represent a position
statement of the College.
Previous | Index | Next